

Comments from Mattias Perjos, CEO

### Organic growth and solid cash flow to end 2025

"We succeeded in growing organically, delivering a record-breaking fourth quarter and organic growth at the upper end of our forecast, 4.9% for the full year. Higher demand for consumables for life supporting ECLS-therapy in the quarter and in Acute Care Therapies contributed to this performance. Sales were also strong in Transplant Care and ventilators. Surgical Workflows continued to strengthen its market-leading position in operating tables and enters 2026 with robust order bookings. In general, sales are more volatile between quarters for Life Science, which grew organically for the full year despite the weaker ending.

Despite headwinds from tariffs (SEK 367 M) and currency effects (SEK 686 M) for the full year 2025 of more than SEK 1 billion compared with last year, we maintained adjusted EBITA margin for the full year in line with 2024 and deliver a solid cash flow. Excluding effects from currency and tariffs, adjusted EBITA margin was 20.3% in the quarter and 16.0% for the full year which is considerably higher than last year. This confirms the positive trend in underlying profitability thanks to our focus on price adjustments, productivity and cost control.

It is gratifying to see that our intensive development efforts have resulted in several important product launches during the quarter. For example Automatiq, the next generation of sterile reprocessing automation systems using smart robotics. This system will ultimately lead to safer and more efficient processes. The system is requested by customers and we have already received the first orders. Ambition is to accelerate development efforts of new products over the coming years which will further strengthen our competitiveness. We continued to make good progress in regulatory compliance. Rotaflow consumables in ECLS received EU MDR approval and our iCast covered stent received PMA for two additional versions, which enhances our competitiveness in the US. European deliveries of our intra-aortic balloon pump Cardiosave, which had its CE certificate reinstated in the fall, are expected to start in the second quarter of 2026. We pushed this date due to a delay in shipment of critical components. The order intake for Cardiosave is strong, meaning that there is clear market demand.

We demonstrated during the year that we are well positioned in priority product categories. In addition, stable healthcare needs and the continued willingness of hospitals to invest are creating favorable conditions for our long-term growth. There's currently high geopolitical uncertainty however based on underlying demand, we expect organic sales growth of 3–5% in 2026. Finally, I would like to express my sincere thanks to all our customers and employees for their important efforts during 2025 in creating value for clinical staff and patients."

### October – December 2025 in brief

- Net sales increased organically by 1.2% (9.2) and the order intake rose by 2.3% organically (7.4).
- Adjusted gross profit amounted to SEK 5,037 M (5,604) and the margin was 49.5% (50.6).
- Adjusted EBITA was SEK 1,809 M (2,143) and the margin 17.8% (19.4).
- Adjusted earnings per share amounted to SEK 4.45 (5.28).
- Free cash flow amounted to SEK 1,190 M (1,693).

### January – December 2025 in brief

- Net sales increased organically by 4.9% (4.9) and the order intake rose by 3.5% organically (6.3).
- Adjusted gross profit amounted to SEK 17,607 M (17,409) and the margin was 50.4% (50.1).
- Adjusted EBITA was SEK 4,880 M (4,869) and the margin 14.0% (14.0).
- Adjusted earnings per share amounted to SEK 11.29 (11.73).
- Free cash flow amounted to SEK 2,652 M (3,284).
- A dividend per share of SEK 4.75 (4.60) is proposed.

**Outlook 2026:** Net sales for 2026 are expected to increase by 3–5% organically, adjusted for the phase-out of Surgical Perfusion<sup>1)</sup>

### Summary of financial performance<sup>2)</sup>

	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>SEK M</b>				
<b>Order intake</b>	<b>8,555</b>	<b>9,273</b>	<b>34,025</b>	<b>34,232</b>
Organic change, %	2.3	7.4	3.5	6.3
<b>Net sales</b>	<b>10,186</b>	<b>11,071</b>	<b>34,969</b>	<b>34,759</b>
Organic change, %	1.2	9.2	4.9	4.9
<b>Adjusted gross profit</b>	<b>5,037</b>	<b>5,604</b>	<b>17,607</b>	<b>17,409</b>
Margin, %	49.5	50.6	50.4	50.1
<b>Adjusted EBITDA</b>	<b>2,228</b>	<b>2,632</b>	<b>6,581</b>	<b>6,646</b>
Margin, %	21.9	23.8	18.8	19.1
<b>Adjusted EBITA</b>	<b>1,809</b>	<b>2,143</b>	<b>4,880</b>	<b>4,869</b>
Margin, %	17.8	19.4	14.0	14.0
<b>Adjusted EBIT</b>	<b>1,717</b>	<b>2,021</b>	<b>4,494</b>	<b>4,549</b>
Margin, %	16.9	18.3	12.9	13.1
<b>Operating profit (EBIT)</b>	<b>1,371</b>	<b>1,084</b>	<b>3,789</b>	<b>2,854</b>
Margin, %	13.5	9.8	10.8	8.2
<b>Profit before tax</b>	<b>1,207</b>	<b>911</b>	<b>3,145</b>	<b>2,282</b>
<b>Net profit for the period</b>	<b>869</b>	<b>668</b>	<b>2,276</b>	<b>1,654</b>
<b>Adjusted net profit for the period</b>	<b>1,213</b>	<b>1,443</b>	<b>3,093</b>	<b>3,211</b>
Margin, %	11.9	13.0	8.8	9.2
<b>Adjusted earnings per share, SEK</b>	<b>4.45</b>	<b>5.28</b>	<b>11.29</b>	<b>11.73</b>
<b>Earnings per share, SEK</b>	<b>3.19</b>	<b>2.44</b>	<b>8.29</b>	<b>6.01</b>
<b>Cash flow from operating activities</b>	<b>1,554</b>	<b>2,039</b>	<b>3,949</b>	<b>4,577</b>
<b>Free cash flow</b>	<b>1,190</b>	<b>1,693</b>	<b>2,652</b>	<b>3,284</b>

1) For more information about the adjustment of the Organic change key ratio, refer to Other information on page 9.

2) See page 3 for calculations of adjusted performance measures.

- The organic order intake for Acute Care Therapies increased, mainly due to double-digit growth in ECLS consumables and Transplant Care. EVH in Cardiovascular Surgery and intra-aortic balloon pumps in Cardiac Assist also contributed.
- Life Science's organic order intake declined in the quarter, mainly due to a weak performance in WIS and Bio-Processing in EMEA and APAC.
- The organic order intake for Surgical Workflows increased following a solid performance in Infection Control and Surgical Workplaces.
- Geographically, the organic order intake trend was positive in both EMEA and Americas. APAC declined, mainly due to a higher order intake in China last year.

- Acute Care Therapies increased its net sales organically, mainly due to the continued strong performance in ventilators, Transplant Care and ECLS therapy.
- Life Science's organic net sales declined, primarily in Bio-Processing and WIS and despite strong growth in Sterile Transfer.
- In Surgical Workflows, organic net sales rose due to growth in operating tables in Surgical Workplaces and consumables in Infection Control.
- Positive organic growth in Americas and EMEA, including strong performances in Germany and Italy. Sales fell in APAC, particularly in China, which nevertheless reported growth for the full-year 2025.
- Recurring revenues increased in the quarter on the back of strong sales of, for example, consumables in ECLS therapy, Sterile Transfer and Transplant Care. Sales of capital goods declined in the quarter, mainly due to WIS and timing effects.

- Net sales declined by SEK 886 M, corresponding to -8.0%.
- Exchange rates had an impact of SEK -1,023 M on sales, corresponding to -9.2%.
- Successful efforts with price adjustments and volumes had an impact of SEK +138 M on sales, corresponding to +1.2%.

## Group performance

### Order intake

Order intake business areas, SEK M	Oct-Dec 2025	Oct-Dec 2024	Org Δ, %	Jan-Dec 2025	Jan-Dec 2024	Org Δ, %
Acute Care Therapies	4,538	4,922	3.1	18,220	17,719	5.6
Life Science	988	1,212	-10.9	4,252	4,601	-2.8
Surgical Workflows	3,029	3,139	6.2	11,553	11,912	2.9
<b>Total</b>	<b>8,555</b>	<b>9,273</b>	<b>2.3</b>	<b>34,025</b>	<b>34,232</b>	<b>3.5</b>

Order intake regions, SEK M	Oct-Dec 2025	Oct-Dec 2024	Org Δ, %	Jan-Dec 2025	Jan-Dec 2024	Org Δ, %
Americas	3,794	4,117	4.5	15,429	15,188	4.5
APAC	1,529	1,880	-7.1	6,311	7,031	-3.2
EMEA	3,232	3,275	4.9	12,285	12,013	6.2
<b>Total</b>	<b>8,555</b>	<b>9,273</b>	<b>2.3</b>	<b>34,025</b>	<b>34,232</b>	<b>3.5</b>

### Net sales


Net sales business areas, SEK M	Oct-Dec 2025	Oct-Dec 2024	Org Δ, %	Jan-Dec 2025	Jan-Dec 2024	Org Δ, %
Acute Care Therapies	5,080	5,526	2.3	18,675	17,948	7.0
Life Science	1,328	1,492	-3.4	4,498	4,552	4.1
Surgical Workflows	3,778	4,053	1.5	11,796	12,258	2.1
<b>Total</b>	<b>10,186</b>	<b>11,071</b>	<b>1.2</b>	<b>34,969</b>	<b>34,759</b>	<b>4.9</b>

Net sales regions, SEK M	Oct-Dec 2025	Oct-Dec 2024	Org Δ, %	Jan-Dec 2025	Jan-Dec 2024	Org Δ, %
Americas	4,068	4,513	1.9	15,686	15,516	4.1
APAC	2,094	2,450	-4.2	6,943	7,061	5.9
EMEA	4,024	4,108	3.7	12,340	12,182	5.3
<b>Total</b>	<b>10,186</b>	<b>11,071</b>	<b>1.2</b>	<b>34,969</b>	<b>34,759</b>	<b>4.9</b>

Net sales specified by capital goods and recurring revenue, SEK M	Oct-Dec 2025	Oct-Dec 2024	Org Δ, %	Jan-Dec 2025	Jan-Dec 2024	Org Δ, %
Capital goods	4,184	4,688	-3.0	11,968	12,421	2.4
Recurring revenue <sup>1)</sup>	6,002	6,384	4.4	23,001	22,338	6.3
<b>Total</b>	<b>10,186</b>	<b>11,071</b>	<b>1.2</b>	<b>34,969</b>	<b>34,759</b>	<b>4.9</b>

1) Consumables, service and spare parts

### Net sales – bridge between Q4 2024 and Q4 2025



## Earnings trend

- Currency effects impacted adjusted gross profit by SEK -573 M and adjusted EBITA by SEK -316 M compared with last year.
- The gross margin declined, mainly due to tariff costs and negative currency effects.
- Adjusted EBITA fell by SEK 334 M, of which tariff costs had an impact of SEK -148 M compared with last year. Despite a favorable mix and continued successful price adjustments, the margin declined 1.6 percentage points.
- Acquisition and restructuring costs are primarily related to the ongoing rationalizations in the organization. Other items affecting comparability primarily comprised higher additional purchase prices related to Paragonix's strong performance in 2025 and write-down of research and development projects in Surgical Workflows.
- Net financial items amounted to SEK -164 M, mainly as a result of lower average interest year-on-year.
- The tax rate for the full-year was 27.6%.

SEK M	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Net sales	10,186	11,071	34,969	34,759
<b>Adjusted gross profit</b>	<b>5,037</b>	<b>5,604</b>	<b>17,607</b>	<b>17,409</b>
Margin, %	49.5	50.6	50.4	50.1
Adjusted operating expenses	-2,809	-2,972	-11,026	-10,764
<b>Adjusted EBITDA</b>	<b>2,228</b>	<b>2,632</b>	<b>6,581</b>	<b>6,646</b>
Margin, %	21.9	23.8	18.8	19.1
Depreciation, amortization and write-downs of intangible assets and tangible assets <sup>1)</sup>	-419	-489	-1,702	-1,776
<b>Adjusted EBITA</b>	<b>1,809</b>	<b>2,143</b>	<b>4,880</b>	<b>4,869</b>
Margin, %	17.8	19.4	14.0	14.0
<b>A Amortization and write-down of acquired intangible assets<sup>1)</sup></b>	<b>-92</b>	<b>-122</b>	<b>-386</b>	<b>-320</b>
<b>Adjusted EBIT</b>	<b>1,717</b>	<b>2,021</b>	<b>4,494</b>	<b>4,549</b>
Margin, %	16.9	18.3	12.9	13.1
<b>B Acquisition and restructuring costs</b>	<b>-39</b>	<b>-622</b>	<b>-397</b>	<b>-898</b>
<b>C Other items affecting comparability<sup>2)</sup></b>	<b>-307</b>	<b>-315</b>	<b>-307</b>	<b>-797</b>
<b>Operating profit (EBIT)</b>	<b>1,371</b>	<b>1,084</b>	<b>3,789</b>	<b>2,854</b>
Net financial items	-164	-173	-644	-571
<b>Profit before tax</b>	<b>1,207</b>	<b>911</b>	<b>3,145</b>	<b>2,282</b>
<b>Adjusted profit before tax</b> (adjusted for A, B and C)	<b>1,645</b>	<b>1,970</b>	<b>4,236</b>	<b>4,298</b>
Margin, %	16.1	17.8	12.1	12.4
Taxes	-338	-243	-869	-628
<b>D Tax on adjustment items<sup>2)</sup></b>	<b>-94</b>	<b>-284</b>	<b>-273</b>	<b>-459</b>
<b>Adjusted net profit for the period</b> (adjusted for A, B, C and D)	<b>1,213</b>	<b>1,443</b>	<b>3,093</b>	<b>3,211</b>
Margin, %	11.9	13.0	8.8	9.2
Of which, attributable to Parent Company shareholders	1,212	1,438	3,076	3,195
<b>Average number of shares, thousands</b>	<b>272,370</b>	<b>272,370</b>	<b>272,370</b>	<b>272,370</b>
<b>Adjusted earnings per share, SEK</b> (adjusted for A, B, C and D)	<b>4.45</b>	<b>5.28</b>	<b>11.29</b>	<b>11.73</b>

1) Excluding items affecting comparability (see Note 4 Depreciation, amortization and write-downs).


2) See Note 6 Adjustment items

## Adjusted EBITA per business area<sup>1)</sup>

SEK M	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>Acute Care Therapies</b>	<b>1,140</b>	<b>1,308</b>	<b>3,763</b>	<b>3,554</b>
Margin, %	22.4	23.7	20.2	19.8
<b>Life Science</b>	<b>172</b>	<b>293</b>	<b>490</b>	<b>608</b>
Margin, %	13.0	19.6	10.9	13.4
<b>Surgical Workflows</b>	<b>624</b>	<b>670</b>	<b>1,077</b>	<b>1,090</b>
Margin, %	16.5	16.5	9.1	8.9
Group functions and other (incl. eliminations)	-127	-128	-450	-383
<b>Total</b>	<b>1,809</b>	<b>2,143</b>	<b>4,880</b>	<b>4,869</b>
Margin, %	17.8	19.4	14.0	14.0

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability.

## Adjusted EBITA – bridge between Q4 2024 and Q4 2025



- Adjusted operating expenses for selling and administration increased organically by 0.8%, mainly due to higher sales activities. Inorganically, these expenses fell by 7.6%.
- The year-on-year difference for other operating income and expenses was mainly attributable to currency effects related to operating receivables and liabilities in foreign currency.

## Adjusted operating expenses

(excluding depreciation, amortization and write-downs and other items affecting comparability)<sup>1)</sup>

SEK M	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Selling expenses	-1,366	-1,414	-5,345	-5,355
Administrative expenses	-1,082	-1,235	-4,182	-4,240
Research and development costs	-331	-397	-1,244	-1,332
Other operating income and expenses	-29	74	-255	164
<b>Total</b>	<b>-2,809</b>	<b>-2,972</b>	<b>-11,026</b>	<b>-10,764</b>

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability.

## Currency impact

SEK M	Oct-Dec 2025	Jan-Dec 2025
Net sales	-1,023	-2,216
Adjusted gross profit	-573	-1,206
Adjusted EBITDA	-355	-768
Adjusted EBITA	-316	-686
Adjusted EBIT	-304	-667

## Cash flow and financial position<sup>1)</sup>

SEK M	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Cash flow before changes in working capital	1,810	2,104	5,137	5,036
Changes in working capital <sup>2)</sup>	-256	-65	-1,188	-459
Net investments in non-current assets	-364	-346	-1,297	-1,294
<b>Free cash flow</b>	<b>1,190</b>	<b>1,693</b>	<b>2,652</b>	<b>3,284</b>
<b>Net interest-bearing cash/debt</b>			<b>9,840</b>	<b>10,467</b>
<i>In relation to adjusted EBITDA<sup>1)</sup> R12M, multiple</i>			1.5	1.6
<b>Net interest-bearing cash/debt, excl. pension provisions</b>			<b>7,482</b>	<b>7,766</b>
<i>In relation to adjusted EBITDA<sup>1)</sup> R12M, multiple</i>			1.1	1.2

1) See Note 6 Adjustment items for items affecting comparability and Note 8 for alternative performance measures.  
2) Non-cash financial items were reclassified to operating liabilities for the 2024 comparative figures.

## Research and development

- Costs for R&D were 7.8% lower year-on-year.
- Capitalized development costs were 7.5% lower compared with last year.
- The year-on-year difference was mainly due to lower costs for quality-related efforts.
- Amortization and write-down of capitalized development costs amounted to SEK -132 M (-414), of which SEK -45 M (-309) in write-downs.

SEK M	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Research and development costs	-514	-558	-1,921	-1,992
Amortization, depreciation and write-downs	-120	-49	-175	-99
<b>Research and development costs, gross</b>	<b>-634</b>	<b>-607</b>	<b>-2,096</b>	<b>-2,091</b>
<i>In relation to net sales, %</i>	6.2	5.5	6.0	6.0
<b>Capitalized development costs</b>	<b>149</b>	<b>161</b>	<b>643</b>	<b>660</b>
<i>In relation to net sales, %</i>	1.5	1.5	1.8	1.9
<b>Research and development costs, net</b>	<b>-485</b>	<b>-446</b>	<b>-1,452</b>	<b>-1,431</b>
<b>Amortization and write-down of capitalized development costs<sup>1)</sup></b>	<b>-132</b>	<b>-414</b>	<b>-430</b>	<b>-707</b>

1) Capitalized development projects

- During the year Getinge has carried out energy efficiency measures and emission-reduction initiatives which has resulted in a reduction of CO2 emissions, primarily due to a higher share of renewable electricity and gas.
- In the Q4-report full-year figures have been added for the recently acquired manufacturing companies Ultra Clean, Healthmark and Quadralene. This resulted in an increase in the Group's total CO2 emissions, energy consumption and water consumption which is also reflected in historical data for 2021-2024. The additional effect for 2025 amounts to 5,979 MWh and 1,209 tons of CO2.
- Water consumption is mainly related to facilities management and testing in production of washers and sterilizers and varies over time depending on production volume. The outcome showed a rising trend due to a higher degree of testing in production and increase in water for facilities at one of our sites.
- It was discovered in the reporting process that data for water consumption had been incorrectly reported. The error related to a manufacturing company and has been corrected by approximately 4,600 m3 for 2025. Action has been taken to reduce the risk of errors occurring in the future.
- The employee engagement index remained stable at 73 out of 100 points and reflected a positive trend in engagement.
- The KPI of Work Related Accident Rate (WRAR) showed a positive trend and Getinge fulfills the target of WRAR <1 2025. Accidents reported are similar between the years, mainly related to ergonomics.
- The regulatory compliance KPI improved compared with the full-year 2024 since the first quarters of 2024 included a higher number of audit findings per audit.
- Regarding online customer training, Respiratory Week was organized in October and resulted in a higher number of webinars, which has a positive impact on the full-year KPI.
- From 2026, Getinge will track a new KPI in business ethics regarding the percentage of employees who have completed training in the Code of Conduct.

## Sustainability developments

This interim report reflects Getinge's double materiality assessment and is based on the ESRS structure to present the company's impact, risks and opportunities from a social, environmental and governance perspective. The aim is to continuously work to minimize the negative impact on people and the environment and to generate sustainable value for customers, employees and other stakeholders.

Key areas	Jan-Dec 2025	Jan-Dec 2024	Δ, % <sup>1)</sup>
<b>Environment, Climate &amp; Energy</b>			
Scope 1 & 2 GHG emissions in production, ton CO <sub>2</sub> equivalents <sup>5)</sup>	4,913	5,432	-9.6
Total energy consumption in production, MWh <sup>5)</sup>	80,887	82,433	-1.9
Percentage of renewable energy of total energy, % <sup>5)</sup>	69	66	3.0*
Water consumption in sites located in water scarce areas, m <sup>3</sup> <sup>2)</sup>	114,691	97,692	17.4
<b>Social</b>			
<b>Own workforce</b>			
Employee engagement, % <sup>3)</sup>	73	71	2.0*
Percentage of female employees, % <sup>4)</sup>	38.2	37.7	0.5*
Percentage of female managers, % <sup>4)</sup>	34.1	34.5	-0.4*
Work Related Accident Rate, WRAR	0.60	0.99	-39.0
<b>Consumers and end-users</b>			
Regulatory compliance, audit findings per audit for quality systems <sup>5)</sup>	1.3	2.5	-47.4
Product quality, field actions per SEK billion in net revenue <sup>5)</sup>	1.0	1.2	-19.2
Online customer training <sup>5)</sup>	53,238	48,486	9.8
<b>Governance</b>			
<b>Business ethics</b>			
Percentage of employees who completed training in business ethics, %	92	90	2*

\*) Change in percentage points

1) Index Jan-Dec 2025/Jan-Dec 2024

2) Eight manufacturing sites were in the scope of the 2024 Sustainability Report. A more detailed investigation has revealed that one of these sites was outside the area of water stress defined as "high" and "extremely high" by the WRI Water Risk Atlas tool Aqueduct. Accordingly, this site is no longer included in the reporting. The annual and quarterly figures have been adjusted and will also be updated retroactively in the 2025 Sustainability Report.

3) Measured and updated every six months

4) Amount at end of period

5) Data was recalculated in 2024. See Getinge's 2024 Sustainability Report for more details

## Acute Care Therapies

Acute Care Therapies offers world-leading solutions for life support in acute health conditions. The offering includes solutions for cardiovascular procedures, efficient handling of organs for transplantation and a broad selection of products and therapies for intensive care.

- The organic order intake for Acute Care Therapies increased, mainly due to double-digit growth in ECLS consumables and Transplant Care. EVH in Cardiovascular Surgery and intra-aortic balloon pumps in Cardiac Assist also contributed.
- Geographically, the organic order intake increased in all regions, except for APAC, where China and Japan declined compared with last year.

- Acute Care Therapies increased its net sales organically, mainly due to the continued strong performance in ventilators, Transplant Care and ECLS therapy.
- Sales grew organically, particularly in Americas, following a solid performance in ECLS therapy and stents among others. EMEA also increased while APAC fell slightly.
- Recurring revenue noted a strong organic performance, with contributions from both consumables and service. Sales of capital goods decreased organically.

- The adjusted gross margin declined by 0.3 percentage points, largely due to negative currency and tariff effects.
- Adjusted selling and administrative expenses increased organically by 5.1%, mainly as a result of higher sales activities. Inorganically, these expenses fell by 4.3%.
- Adjusted EBITA declined by SEK 168 M, largely due to negative currency and tariff effects despite price adjustments, volume and a favorable product mix. The margin fell by 1.3 percentage points.
- Currency effects impacted sales by SEK -572 M, adjusted gross profit by SEK -356 M and adjusted EBITA by SEK -202 M compared with last year.

### Order intake and net sales

Order intake regions, SEK M	Oct-Dec 2025	Oct-Dec 2024	Org Δ, %	Jan-Dec 2025	Jan-Dec 2024	Org Δ, %
Americas	2,411	2,640	3.6	9,791	9,120	7.5
APAC	798	1,092	-16.0	3,583	3,897	-0.9
EMEA	1,330	1,190	19.3	4,846	4,702	7.2
<b>Total</b>	<b>4,538</b>	<b>4,922</b>	<b>3.1</b>	<b>18,220</b>	<b>17,719</b>	<b>5.6</b>

Net sales regions, SEK M	Oct-Dec 2025	Oct-Dec 2024	Org Δ, %	Jan-Dec 2025	Jan-Dec 2024	Org Δ, %
Americas	2,535	2,753	4.3	9,893	9,223	7.5
APAC	1,091	1,235	-0.6	3,928	3,983	6.2
EMEA	1,454	1,538	1.0	4,854	4,742	6.5
<b>Total</b>	<b>5,080</b>	<b>5,526</b>	<b>2.3</b>	<b>18,675</b>	<b>17,948</b>	<b>7.0</b>

Net sales specified by capital goods and recurring revenue, SEK M	Oct-Dec 2025	Oct-Dec 2024	Org Δ, %	Jan-Dec 2025	Jan-Dec 2024	Org Δ, %
Capital goods	1,395	1,599	-3.7	4,267	4,318	6.1
Recurring revenue <sup>1)</sup>	3,686	3,927	4.7	14,407	13,631	7.2
<b>Total</b>	<b>5,080</b>	<b>5,526</b>	<b>2.3</b>	<b>18,675</b>	<b>17,948</b>	<b>7.0</b>

1) Consumables, service and spare parts

### Earnings trend<sup>1)</sup>

SEK M	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>Net sales</b>	<b>5,080</b>	<b>5,526</b>	<b>18,675</b>	<b>17,948</b>
<b>Adjusted gross profit</b>	<b>2,946</b>	<b>3,224</b>	<b>10,897</b>	<b>10,417</b>
Margin, %	58.0	58.3	58.4	58.0
<b>Adjusted EBITDA</b>	<b>1,345</b>	<b>1,553</b>	<b>4,616</b>	<b>4,474</b>
Margin, %	26.5	28.1	24.7	24.9
Depreciation, amortization and write-downs of intangible assets and tangible assets	-205	-245	-853	-920
<b>Adjusted EBITA</b>	<b>1,140</b>	<b>1,308</b>	<b>3,763</b>	<b>3,554</b>
Margin, %	22.4	23.7	20.2	19.8

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability.

### Events in the business area in the quarter

- Premarket Approval (PMA) received for the iCast covered stent in large diameter (12 mm) and lengths of 32 mm and for 10 mm × 59 mm lengths.
- CE certificate received under the EU MDR for the PLS set used in extracorporeal circulation for cardiac and/or pulmonary support.
- PiCCO, our minimally invasive hemodynamic monitoring system, is now included in the European Society of Intensive Care Medicine's Guideline on Circulatory Shock.
- The 510(k)-submission for the intra-aortic balloon pump, Cardiosave, has been pushed to the second quarter of 2026 due to a delay in shipment of critical components. The order intake for Cardiosave is strong, meaning that there is clear market demand.

## Life Science

*Life Science offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in pharmaceutical and medical device production and with the aim to strengthen integrity of results in biomedical research.*

- Life Science's organic order intake declined in the quarter, mainly due to a weak performance in WIS and Bio-Processing in EMEA and APAC. Services performed positively.
- The organic order intake declined in all regions and mainly in EMEA, where Italy and Germany experienced a challenging quarter.

- Life Science's organic net sales declined, primarily in Bio-Processing and WIS despite strong growth in Sterile Transfer.
- Organic sales increased in EMEA mainly due to healthy growth in Sterile Transfer and isolators. The decline in Americas and APAC was mainly due to WIS.
- The trend in recurring revenue was favorable, driven by continued strong growth in Sterile Transfer and service. Capital goods declined primarily in WIS and Bio-Processing.

- The adjusted gross margin declined by 6.1 percentage points, mainly due to volume, currencies and tariffs.
- Adjusted selling and administrative expenses declined organically by -11.2% due to lower personnel related costs and a continued focus on productivity. Inorganically, these expenses fell by -17.7%.
- Adjusted EBITA fell by SEK 121 M, mainly due to lower gross profit. The margin declined by 6.6 percentage points.
- Currency effects impacted sales by SEK -114 M, adjusted gross profit by SEK -58 M and adjusted EBITA by SEK -47 M compared with last year.

### Order intake and net sales

Order intake regions, SEK M	Oct-Dec 2025	Oct-Dec 2024	Org Δ, %	Jan-Dec 2025	Jan-Dec 2024	Org Δ, %
Americas	345	407	-3.7	1,469	1,862	-15.4
APAC	121	158	-12.5	520	573	-2.4
EMEA	521	647	-15.1	2,263	2,166	8.0
<b>Total</b>	<b>988</b>	<b>1,212</b>	<b>-10.9</b>	<b>4,252</b>	<b>4,601</b>	<b>-2.8</b>

Net sales regions, SEK M	Oct-Dec 2025	Oct-Dec 2024	Org Δ, %	Jan-Dec 2025	Jan-Dec 2024	Org Δ, %
Americas	481	587	-8.2	1,660	1,937	-7.9
APAC	165	219	-15.1	603	559	15.8
EMEA	682	686	4.4	2,235	2,057	12.3
<b>Total</b>	<b>1,328</b>	<b>1,492</b>	<b>-3.4</b>	<b>4,498</b>	<b>4,552</b>	<b>4.1</b>

Net sales specified by capital goods and recurring revenue, SEK M	Oct-Dec 2025	Oct-Dec 2024	Org Δ, %	Jan-Dec 2025	Jan-Dec 2024	Org Δ, %
Capital goods	599	779	-16.8	1,872	1,970	0.1
Recurring revenue <sup>1)</sup>	729	714	11.2	2,626	2,582	7.2
<b>Total</b>	<b>1,328</b>	<b>1,492</b>	<b>-3.4</b>	<b>4,498</b>	<b>4,552</b>	<b>4.1</b>

1) Consumables, service and spare parts

### Earnings trend<sup>1)</sup>

	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>SEK M</b>				
<b>Net sales</b>	<b>1,328</b>	<b>1,492</b>	<b>4,498</b>	<b>4,552</b>
<b>Adjusted gross profit</b>	<b>468</b>	<b>617</b>	<b>1,676</b>	<b>1,808</b>
Margin, %	35.2	41.3	37.3	39.7
<b>Adjusted EBITDA</b>	<b>227</b>	<b>347</b>	<b>712</b>	<b>818</b>
Margin, %	17.1	23.3	15.8	18.0
Depreciation, amortization and write-downs of intangible assets and tangible assets	-56	-55	-222	-211
<b>Adjusted EBITA</b>	<b>172</b>	<b>293</b>	<b>490</b>	<b>608</b>
Margin, %	13.0	19.6	10.9	13.4

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability.

### Events in the business area in the quarter

- Siemens' SIMATIC WinCC Unified system, which is industry standard, is integrated into the new generation of cGMP washers and sterilizers, delivering an open and flexible interface that supports streamlined operations, efficient data management, and secured data integrity. The interface simplifies procurement, validation and reduces training needs, addressing digitalization challenges in the pharmaceutical industry.

## Surgical Workflows

*Surgical Workflows offers products and solutions to serve as an end-to-end partner for optimizing the quality, safety and capacity usage of the sterile supply departments and operating rooms.*

- The organic order intake for Surgical Workflows increased following a solid performance in Infection Control and Surgical Workplaces.
- Growth was positive in all regions and particularly strong in North America and APAC, with China and Japan representing the main contributors.

- In Surgical Workflows, organic net sales rose due to growth in operating tables in Surgical Workplaces and consumables in Infection Control.
- Geographically, EMEA reported growth in all product categories. The volatile sales profile in Digital Health Solutions contributed to the decline in APAC.
- Growth in both recurring revenue and capital goods in the quarter.

- The adjusted gross margin declined by 0.5 percentage points, mainly due to negative currency effects, tariffs and inflation.
- Adjusted selling and administrative expenses declined organically by 0.8% as a result of the continued focus on productivity. Inorganically, these expenses fell by 9.0%.
- Adjusted EBITA fell by SEK 46 M, following lower gross profit. The margin was unchanged.
- Currency effects impacted sales by SEK -338 M, adjusted gross profit by SEK -159 M and adjusted EBITA by SEK -69 M compared with last year.

### Order intake and net sales

Order intake regions, SEK M	Oct-Dec 2025	Oct-Dec 2024	Org Δ, %	Jan-Dec 2025	Jan-Dec 2024	Org Δ, %
Americas	1,038	1,070	9.9	4,168	4,206	6.7
APAC	610	631	9.8	2,208	2,561	-6.9
EMEA	1,380	1,438	2.0	5,176	5,145	4.6
<b>Total</b>	<b>3,029</b>	<b>3,139</b>	<b>6.2</b>	<b>11,553</b>	<b>11,912</b>	<b>2.9</b>

Net sales regions, SEK M	Oct-Dec 2025	Oct-Dec 2024	Org Δ, %	Jan-Dec 2025	Jan-Dec 2024	Org Δ, %
Americas	1,053	1,173	1.4	4,133	4,356	2.1
APAC	837	996	-6.2	2,412	2,519	3.3
EMEA	1,888	1,884	5.7	5,251	5,383	1.4
<b>Total</b>	<b>3,778</b>	<b>4,053</b>	<b>1.5</b>	<b>11,796</b>	<b>12,258</b>	<b>2.1</b>

Net sales specified by capital goods and recurring revenue, SEK M	Oct-Dec 2025	Oct-Dec 2024	Org Δ, %	Jan-Dec 2025	Jan-Dec 2024	Org Δ, %
Capital goods	2,190	2,310	2.1	5,829	6,133	0.4
Recurring revenue <sup>1)</sup>	1,587	1,743	0.7	5,967	6,125	3.7
<b>Total</b>	<b>3,778</b>	<b>4,053</b>	<b>1.5</b>	<b>11,796</b>	<b>12,258</b>	<b>2.1</b>

1) Consumables, service and spare parts

### Earnings trend<sup>1)</sup>

SEK M	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>Net sales</b>	<b>3,778</b>	<b>4,053</b>	<b>11,796</b>	<b>12,258</b>
<b>Adjusted gross profit</b>	<b>1,623</b>	<b>1,763</b>	<b>5,034</b>	<b>5,185</b>
Margin, %	43.0	43.5	42.7	42.3
<b>Adjusted EBITDA</b>	<b>781</b>	<b>858</b>	<b>1,697</b>	<b>1,728</b>
Margin, %	20.7	21.2	14.4	14.1
Depreciation, amortization and write-downs of intangible assets and tangible assets	-157	-187	-619	-638
<b>Adjusted EBITA</b>	<b>624</b>	<b>670</b>	<b>1,077</b>	<b>1,090</b>
Margin, %	16.5	16.5	9.1	8.9

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability.

### Events in the business area in the quarter

- Launch of the utility-efficient Aquadis 44 washer-disinfector, which helps hospitals reduce costs and meet environmental targets.
- Launch of Automatiq, the new family of next generation automated solutions that combines smart robotics, intelligent conveyor systems and advanced software to achieve safer, more consistent and less labor-intensive sterile reprocessing.

## Other information

### Events after the end of the reporting period

Geopolitical debate and the turbulent global environment continue to dominate the market. We are monitoring developments closely and continuously assessing the potential impact on our operations.

### Seasonal variations

Getinge's sales and earnings are affected by seasonal variations. The highest net sales are usually generated in the fourth quarter, followed by the second, third and first quarters. The shares of sales derived from capital goods and recurring revenue also normally changes during the year, with a higher share of sales of capital goods toward the end of the year.

### Transactions with related parties

Getinge carried out normal commercial transactions with companies in the Carl Bennet AB sphere, which comprised the sale and purchase of goods and services. In addition, no other significant transactions with related parties occurred during the period other than transactions with subsidiaries.

### Forward-looking information

This report contains forward-looking information based on the current expectations of company management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding finances, market and competition, changes in legal and regulatory requirements and other political measures, and fluctuations in exchange rates.

### Update of Organic change key ratio

The definition of Organic change has been adjusted from the first quarter of 2026 to also exclude phase-outs of product categories. The change has been made to provide a more fair presentation of underlying growth even when phase-outs are currently being made. Quarterly comparative figures for 2025, excluding the Surgical Perfusion product category, are published on Getinge's website under Reports and Presentations,

<https://www.getinge.com/int/company/investors/reports-presentations/>.

Surgical Perfusion's sales in 2026 are expected to decline from approximately SEK 250 M to SEK 50 M.

### Getinge's financial targets 2024–2028 and dividend policy

- Average adjusted earnings per share growth: >12%\*
- Getinge's dividend policy is to pay dividends of 30-50% of net profit to shareholders.

### Getinge's sustainability targets

#### Environment

- Reduce Scope 1 and 2 emissions by 90% by 2030\*\*
- Reduce Scope 3 emissions by 25% by 2030, and by 90% by 2050\*\*
- Reduce energy consumption in production by 20% by 2030\*\*
- Reduce water consumption in sites located in water scarce areas by 20% by 2030\*\*
- No waste to landfill by 2030, excluding material required by local regulations to be landfilled

#### Social

- Employee engagement: >70%

- Reduce work-related accidents in relation to working hours (Work Related Accident Rate, WRAR) to less than 1 by 2025
- Ensure equal employment opportunity and non-discrimination across all levels of the organization Follow-up % female vs male managers and employees
- Quality regulatory compliance, audit results/inspection: <1.5 deviation

**Governance**

- All employees are properly trained in Business ethics

*\*Base year 2023*

*\*\*Base year 2021*

**Dividend**

The Board of Directors and CEO propose a dividend for 2025 of SEK 4.75 (4.60) per share, a combined total of SEK 1,294 M (1,253). The Board's dividend proposal for 2025 is a deviation from the policy of paying dividends of 30–50% of net profit. The proposal is based on the favorable cash flow generated by the operations. The final date for trading including the right to receive dividends is April 21, 2026 and the proposed record date is April 23, 2026. Euroclear expects to distribute the dividend to shareholders on April 28, 2026.

**2026 Annual General Meeting**

Getinge AB's Annual General Meeting will be held on April 21, 2026 in Halmstad, Sweden. Shareholders wishing to have a matter addressed at the Annual General Meeting can submit their proposal to Getinge's Board Chairman by e-mail: [arenden.bolagsstamma@getinge.com](mailto:arenden.bolagsstamma@getinge.com), or by mail at the following address: Getinge AB, Att: Bolagsstämmaärenden, Box 8861, SE-402 72 Gothenburg, Sweden. To ensure inclusion in the notice and the agenda of the AGM, proposals must be received by the company not later than March 3, 2026.

# Risk management

## External risks

	<b>Description</b>	<b>Potential consequences</b>	<b>Management</b>
<b>External shocks, such as geopolitical risks, natural disasters, terrorism, pandemics, etc.</b>	Rapidly emerging situations, which could affect large geographical areas, a single country, a region or a specific facility.	The primary risk of such events is that employees could be injured. In addition, operations can be disrupted, which could have a negative impact on sales and earnings. Price increases for customers is another scenario.	Active business intelligence can identify some of these risks at an early stage, which enables the Group to adapt to the changed circumstances. The Group is working actively on continuity risks. This also includes scenarios based on external shocks as part of Getinge's proactive risk management. Getinge conducts operations in Russia in accordance with international sanctions and regulations via a small sales company. The activities in the country are currently limited to fulfilling existing customer commitments. However, the circumstances for conducting operations in the country have gradually deteriorated. Getinge does not conduct any manufacturing operations in either Russia or Ukraine and has no major suppliers in these countries. When Russia invaded Ukraine in 2022, the Group's sales in Russia and Ukraine represented less than 1% of the Group's total net sales and equity. Despite the limited direct impact that the invasion has had on Getinge's operations in Russia and Ukraine, the Russian invasion of Ukraine may nevertheless have a negative impact on the development of the Group's earnings and position. However, it is difficult at the current time to assess the future consequences of the conflict and its impact on the Group.
<b>Interruptions in supply chains / dependence on external suppliers</b>	Critical components manufactured by external suppliers are a vital part of Getinge's production chain. Serious production disruptions may arise if these components are not supplied on schedule.	As a consequence, vital equipment may not be delivered to customers, which may make it difficult or impossible to provide necessary healthcare.	Getinge is monitoring and actively adapting its operations based on escalating developments during 2025 regarding geopolitical friction and higher trade barriers, such as tariffs and increased volatility in currency markets. As a consequence, a potentially higher risk premium in the capital markets cannot be ruled out. The Group addresses this through a solid capital-raising process and a clear overview of its goods flows, and thereby also the impact of tariffs and other trade barriers. Getinge has a geographically diversified purchasing and production strategy which partly can help to mitigate any negative consequences.
<b>Risks related to healthcare reimbursement systems</b>	Political decisions can change the conditions for healthcare through changed reimbursement models for healthcare providers.	Changes to reimbursement systems could have significant effects on specific markets, with budget cuts or deferred funding potentially impacting the operations.	Getinge can state that there is a risk of temporary business interruptions, for example, due to supply constraints for key components such as semiconductors, as a result of the uncertain global security situation. Getinge actively monitors critical suppliers, starting as early as when the partnership is established and continuing with routine evaluations. The Purchasing organization has tools for assessing risk and receives regular training in this area. The Group also works on ensuring that it has adequate levels of critical components in stock, in its own operations or with the relevant supplier. Interruptions of critical deliveries are managed as an important part of activities related to business continuity risks. See "Business interruptions."
<b>New competitors and new technologies</b>	Certain markets and product segments have niche players who offer solutions outside customary market behavior.	These competitors could capture market shares from established companies, including Getinge, which could result in lower sales and earnings.	Although it is difficult to influence this risk directly, since decisions are outside the Group's control, it is mitigated by the presence in a large number of markets, which reduces the overall impact of individual changes.
<b>Increased expectations and new laws and regulations related to sustainability</b>	The sustainability requirements and expectations placed on Getinge as a company are changing, and the scope is increasing rapidly.	Getinge's failure to meet the ever-more stringent environmental, social and governance requirements could have negative consequences on the company's reputation, operations and financial earnings. It may also impact the company's ability to recruit and retain competent staff, and risk disqualifying the company from participating in tenders with specific requirements.	By engaging with stakeholders and improving its materiality assessment and ERM process, Getinge increases its understanding of the expectations placed on the company. It is also beneficial that the company has adopted the focus areas that are to be prioritized moving forward. In addition, the company has developed its sustainability framework, focusing on the products and solutions placed on the market to ensure quality and corporate responsibility. This also leads to employee engagement. The company reports annually on its performance in sustainability in a transparent manner and is making preparations ahead of the forthcoming CSRD.
<b>Increasing competition for public funds</b>	Reduced public budgets for investing in medical devices impacts the total market potential.	Increased competition for limited public funds may lead to reduced funding for medical device investments, which in turn negatively impacts Getinge's sales figures.	Getinge works actively to offer solutions that improve the efficiency of healthcare, which is believed to generate healthy demand even where budgets are constrained.

## Operational risks

	Description	Potential consequences	Management
<b>Quality risks from a regulatory perspective</b>	A large part of Getinge's product range is subject to strict legislation requiring extensive assessments, quality controls and detailed documentation.	It cannot be ruled out that Getinge's operations, financial position and earnings may be negatively impacted in the future if the company is unable to comply with regulatory requirements or if these requirements change.	To limit these risks, Getinge conducts extensive quality and regulatory activities. The Quality Compliance, Regulatory & Medical Affairs function has a representative in the Getinge Executive Team and also on the management teams of each business area, and in all R&D and production units. In addition, Getinge's sales force and service technicians receive quality and regulatory training every other year, and then have their certification renewed, which is a requirement for representing the company. Getinge conducts extensive research and development to ensure that the product portfolio meets all existing and future quality and regulatory requirements. The majority of the production facilities have ISO 13485 and/or ISO 9001 certification. In summary, Getinge invests significant resources in quality and regulatory matters, which is a top priority of the Group's strategy. As previously reported in the first quarter of 2023, the notifying body TÜV SÜD decided to temporarily suspend the CE certificate for Getinge's HLS and PLS sets for ECLS therapy and for Getinge's intra-aortic balloon pumps. As a result, the company initiated corrective actions to regain CE certification for these products. At the end of September 2024, TÜV SÜD reinstated Getinge's CE certificate for HLS and PLS sets, with certain conditions. The temporary suspension of Getinge's Cardiosave Intra-Aortic Balloon Pump, effective from March 2024, was extended until July 1, 2025. At the beginning of August 2025, TÜV SÜD reinstated Getinge's CE mark for Cardiosave under certain conditions which Getinge has promised to fulfill. On May 8, 2024, the FDA sent a letter to healthcare providers in the US. The letter does not refer to any new field actions, but healthcare providers are encouraged to move from using Getinge's Cardiosave, Cardiohelp and HLS sets to alternative products and to continue to use Getinge's products only if no other options are available. As a result of the FDA's letter, Getinge has decided to suspend marketing activities for the relevant products in the US until outstanding actions related to quality improvements have been taken and approved. Sales of these products are restricted to customers who do not have any other alternatives. On November 15, 2024, the FDA published a Letter to Health Care Providers on its website, reminding them of the voluntary medical device removal and supply concerns related to all of Getinge's VasoView Hemopro Endoscopic Vessel Harvesting (EVH) Systems. Actions are being taken as agreed with the FDA.
<b>Product quality from a customer perspective</b>	In certain cases, Getinge's products do not meet customer expectations.	Product quality shortcomings could lead to customer seeking out alternative suppliers, which in turn could negatively impact sales and profitability over time.	Getinge applies a far-reaching quality process to ensure a high and even level of quality, which is an ongoing process that results in continuous improvements. When quality fails, it is important to rapidly rectify the fault during the first service visit. Getinge closely monitors the "first-time fix" factor of its services operations and works actively to make improvements.
<b>Product liability risks</b>	Healthcare suppliers run a risk, like other players in the healthcare industry, of being subject to product liability and other legal claims.	Such claims can involve large amounts and significant legal expenses. Getinge carries the customary indemnity and product liability insurances, but there is a risk that this insurance coverage may not fully cover product liability and other claims.	The most important way of managing these risks is the extensive quality-related and regulatory activities performed by the Group. Sources of potential future claims for damages are monitored through active incident reporting. Corrective and protective action (CAPA) is initiated when necessary to investigate the underlying cause, after which the product design may be corrected to remedy the fault. The settlement process regarding the Multidistrict Litigation (MDL) for surgical mesh implants, which Getinge announced previously, has been completed and payment of the majority of the settlement amount was made in the first quarter of 2023. The settlement is not an admission of liability or wrongdoing by the company. Getinge will continue to defend against any litigation that cannot be resolved under the final agreement. Costs for such processes are not expected to be material.
<b>Information and data security</b>	Leaks of confidential information or hacking into the Group's IT system resulting in restricted availability or interruptions of business-critical systems. In this context, extortion or sabotage cannot be excluded either.	Hacking into IT systems could lead to business interruptions. A loss of sensitive information may adversely affect confidence in the company. Leaks of personal data could lead to high fines.	Getinge has global IT services that ensure efficiency, coordination and security. Getinge's IT structure in production is largely decentralized, which reduces the consequences of certain cyber risks by spreading the risks across different systems. Getinge has centralized identity management and conducts extensive surveillance and monitoring of the central infrastructure to quickly detect and counteract security threats via its security operations center (SOC). Getinge regularly trains all employees to reduce cyber risks based on human factors.
<b>Deficiencies in cybersecurity</b>	Security deficiencies in the Group's digital offering, such as connected machines at customer sites and stricter legal requirements for processing personal data. In this context, extortion or sabotage cannot be excluded either.	Restricted availability of equipment delivered by Getinge to its customers, which could result in interruptions to the hospital operations and it not being possible to offer patients sufficient care in critical situations.	Getinge works diligently and systematically, following a risk-based approach, to ensure the integrity of its connected equipment. By continuously evaluating and prioritizing security risks, we can effectively protect both our systems and our customers' data. Comprehensive access testing is carried out before these solutions are offered to the Group's customers so as to identify and rectify potential vulnerabilities.
<b>Business interruptions</b>	Unforeseen events, such as natural disasters or fires, etc. can cause disruptions to production or the supply chain.	Such events may result in costly or delayed deliveries or non-delivery of products to Getinge's customers, which may adversely affect the Group's earnings.	Getinge takes continuous preventive action to ensure a high level of availability and delivery reliability, including regular inspections of the production facilities with the help of external expertise.
<b>Non-compliance with laws and regulations mainly on business ethics</b>	Breaches of laws and regulations related to, for example, competition, anti-corruption, AI, cyber security, data protection or trade restrictions.	Breaches of these regulations could lead to fines, sanctions and have a negative impact on the Getinge brand.	Getinge has previously provided information about ongoing investigations and agreements with the authorities regarding anti-competitive procedures in the sale of medical devices in Brazil. The process with the Brazilian federal authority, Comptroller General of the Union (CGU), is still ongoing. During the third quarter of 2024, Getinge made, in line with applicable accounting standards, a provision of SEK 482 M related to anticipated costs related to this process. The provision is the result of an ongoing constructive dialogue to reach a conclusion in the negotiations with the CGU. The final and definitive costs will be determined once the negotiations have been concluded, and such an amount could be lower or higher than the provision that has now been made. No information emerged in the period that would cause a change in the provision.

**Dependence on meeting climate targets**

Getinge is dependent on meeting the climate targets set to reach net zero emissions by 2050 that were approved by the SBTi. Getinge's analysis shows that the majority of emissions come from the purchases of goods, logistics and the use of sold products. As a result, the company does not have full control over its emissions and cannot therefore directly control their reduction.

If Getinge does not meet its climate targets, it could have a significant negative impact on the company's reputation and operations, in addition to negative climate impacts.

In addition to the investigations with CGU, Getinge has previously communicated that settlement agreements have been reached with the Brazilian Federal Prosecutor's Office (Ministério Pùblico Federal) in 2018 and the competition authority, Administrative Council for Economic Defense (CADE) in 2019, both related to anti-competitive practices relating to the sale of medical devices. It cannot be ruled out that any further agreements with authorities may have a material impact on the company's financial earnings and position, but cannot currently be estimated neither in terms of amount nor timing. Getinge has a zero tolerance policy when it comes to contraventions of these regulations. The Group's Code of Conduct is very clear in this respect.

The EVP Sustainability, Legal & Compliance represents the Ethics & Compliance function on the Getinge Executive Team, which highlights the high priority of these issues. A training program in business ethics is provided on an ongoing basis and the aim is for all employees to undergo such training at least once a year. The regulations also apply to external distributors who sell Getinge products.

Getinge is dependent on meeting the climate targets set to reach net zero emissions by 2050 that were approved by the SBTi. Getinge's analysis shows that the majority of emissions come from the purchases of goods, logistics and the use of sold products. As a result, the company does not have full control over its emissions and cannot therefore directly control their reduction.

## Strategic risks

	<b>Description</b>	<b>Potential consequences</b>	<b>Management</b>
<b>Lack of future skills</b>	Risk of dependency on key people including lack of succession planning and ineffective processes to identify and spread critical know-how within the organization. Also the risk of being unable to attract and retain the right talent and skills.	A lack of future skills could lead to higher staff turnover, operational disruptions and damage the Getinge brand. In the future, it may have a negative impact on Getinge's long-term sustainability and growth, and ultimately affect Getinge's ability to attract and retain talent.	Getinge is continuously improving the succession planning process to ensure the global development of talent. Getinge is focusing on talent mobility and knowledge sharing and strives to create a culture and leadership that attracts both new and existing talent. Getinge's aim is to be a company where everyone can thrive and grow.
<b>Digitization and innovation</b>	Getinge's future growth depends on successful product development, particularly in digitalization. Innovation is crucial for maintaining and strengthening the company's leading position.	Innovation efforts are costly and it is not possible to guarantee that developed products will be commercially successful, which could result in impairment. In the long term, the Group's market position could be negatively affected if Getinge is unsuccessful in this area.	As a means of maximizing the return on investments in research and development, the Group applies a structured selection and planning process that includes careful analyses of the market, technological progress, choice of production method and selection of subcontractors. The actual development work is also conducted in a structured manner and each project undergoes a number of fixed controls. Getinge is particularly concerned with ensuring access to the right skills, retaining key individuals, being an attractive employer to recruit talent externally, and identifying and developing talent within the organization.
<b>Fragmented product portfolio</b>	Getinge's product portfolio consists, to a certain extent, of a large number of acquisitions that were made throughout the years within a variety of product categories.	An offering to our customers that, in certain parts, is too diverse could lead to Getinge lacking the critical mass needed to conduct fully efficient operations in all product categories.	Efforts are being made to enhance the efficiency of the customer offering under the framework of the ongoing strategic activities in each business area. The introduction of the new EU Medical Device Regulation means priorities need to be made regarding the certification of products under the new regulatory framework. Products have been selected that, over the long term, will be a part of the customer offering, which will lead to increased concentration as well as streamlining.
<b>Risks related to intellectual property rights</b>	Getinge's leading positions in many product segments are based on patent and trademark rights, which could lead to disputes with competitors.	Costly disputes over intellectual property rights could reduce the return on investment in research and development. It cannot be ruled out that the costs that could arise associated with this could be material.	Getinge closely monitors the activities of its competitors and actively defends its intellectual property rights through legal processes if necessary.
<b>Financial risks</b>	Getinge is exposed to a number of financial risks in its operations. Financial risks principally pertain to currency risks, interest-rate risks, and credit and counterparty risks.	Fluctuations in exchange rates and interest rates and changes in counterparties' credit profiles could adversely affect the Group's income statement and balance sheet.	Risk management is regulated by the finance policy adopted by the Board and a Treasury directive decided by the Getinge Executive Team based on the finance policy. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with the Getinge Executive Team and the treasury function. For more detailed information concerning these risks, refer to Note 18 of the Annual Report.
<b>Profitability dependent on certain products and markets</b>	Some products and markets contribute more to overall profitability.	If sales volumes in these markets were to decrease, it could have a negative impact on the Group's profitability.	Getinge works actively to monitor profitability per product and market in order to ensure profitability over time. To reduce the sensitivity of profitability, the Group actively works on ensuring that it has the right cost level in relation to the current price levels in the market. Getinge also works actively to establish itself in new markets.
<b>Transferring the product portfolio</b>	Long lead times in research and development due to comprehensive regulations and long validation processes are hampering rapid development to more sustainable product and packaging solutions. The medical device market is strictly regulated, partly to ensure patient safety, which can affect how quickly Getinge's products can become sustainable.	If it is not possible to transfer Getinge's product and packaging solutions to more sustainable solutions quickly enough, there is a risk that Getinge's reputation and competitiveness could decline.	Getinge will always prioritize patient safety and follow applicable regulations. Without impacting our fundamental approach, the company has expanded the implementation of eco-design principles into its development process and has begun to carry out life cycle assessments of its product and packaging solutions to ensure that advances can be made when the opportunity arises.

**Assurance**

The Board of Directors and CEO assure that the interim report provides a true and fair review of the Parent Company and the Group's operations, position and earnings and describes the material risks and uncertainties faced by the Parent Company and the Group.

**Gothenburg, January 27, 2026**

<b>Johan Malmquist</b> Chairman, AGM-elected Board member	<b>Carl Bennet</b> Vice Chairman, AGM-elected Board member	<b>Johan Bygge</b> AGM-elected Board member
<b>Cecilia Daun Wennborg</b> AGM-elected Board member	<b>Ulrika Dellby</b> AGM-elected Board member	<b>Dan Frohm</b> AGM-elected Board member
<b>Mattias Perjos</b> President & CEO, AGM-elected Board member	<b>Malin Persson</b> AGM-elected Board member	<b>Kristian Samuelsson</b> AGM-elected Board member
<b>Fredrik Brattborn</b> Board member Representative of the Swedish Metalworkers' Union	<b>Åke Larsson</b> Board member Representative of the Swedish Association of Graduate Engineers	

# Consolidated financial statements

## Condensed consolidated income statement

SEK M	Note	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Net sales	2, 3	10,186	11,071	34,969	34,759
Cost of goods sold		-5,382	-6,018	-18,315	-18,606
<b>Gross profit</b>	2, 3, 4	<b>4,803</b>	<b>5,053</b>	<b>16,654</b>	<b>16,153</b>
Selling expenses		-1,574	-1,618	-6,050	-5,979
Administrative expenses		-1,182	-1,340	-4,587	-4,654
Research and development costs		-485	-446	-1,452	-1,431
Acquisition costs		-10	-5	-24	-50
Restructuring costs		-29	-617	-374	-848
Other operating income and expenses		-153	56	-379	-336
<b>Operating profit (EBIT)</b>	3, 4	<b>1,371</b>	<b>1,084</b>	<b>3,789</b>	<b>2,854</b>
Net financial items	3	-164	-173	-644	-571
<b>Profit after financial items</b>	3	<b>1,207</b>	<b>911</b>	<b>3,145</b>	<b>2,282</b>
Taxes		-338	-243	-869	-628
<b>Net profit for the period</b>		<b>869</b>	<b>668</b>	<b>2,276</b>	<b>1,654</b>
<hr/>					
<i>Attributable to:</i>					
Parent Company shareholders		868	664	2,258	1,638
Non-controlling interests		1	5	17	16
<b>Net profit for the period</b>		<b>869</b>	<b>668</b>	<b>2,276</b>	<b>1,654</b>
Earnings per share, SEK <sup>1)2)</sup>		3.19	2.44	8.29	6.01
Weighted average number of shares for calculation of earnings per share (000s)		272,370	272,370	272,370	272,370

1) Before and after dilution

2) Attributable to the Parent Company shareholders

## Consolidated statement of comprehensive income

SEK M	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>Net profit for the period</b>	<b>869</b>	<b>668</b>	<b>2,276</b>	<b>1,654</b>
<hr/>				
<i>Other comprehensive income</i>				
<b>Items that cannot be restated in profit for the period</b>				
Actuarial gains/losses pertaining to defined-benefit pension plans	90	-6	165	31
Tax attributable to items that cannot be restated in profit	-22	5	-45	-3
<b>Items that can later be restated in profit for the period</b>				
Translation differences	-652	1,814	-4,160	2,063
Hedging of net investments	-104	329	-754	393
Cash flow hedges	3	16	-5	12
Tax attributable to items that can be restated in profit	21	-71	156	-83
<b>Other comprehensive income for the period, net after tax</b>	<b>-663</b>	<b>2,088</b>	<b>-4,643</b>	<b>2,412</b>
<b>Total comprehensive income for the period</b>	<b>206</b>	<b>2,756</b>	<b>-2,367</b>	<b>4,066</b>
<hr/>				
<i>Comprehensive income attributable to:</i>				
Parent Company shareholders	205	2,747	-2,373	4,038
Non-controlling interests	1	9	6	28
<b>Total comprehensive income for the period</b>	<b>206</b>	<b>2,756</b>	<b>-2,367</b>	<b>4,066</b>

## Condensed consolidated balance sheet

SEK M	Note	December 31 2025	December 31 2024
Intangible assets		33,513	39,242
Tangible assets		3,469	3,902
Right-of-use assets		1,470	1,795
Financial assets		34	47
Deferred tax assets		792	770
<b>Total non-current assets</b>		<b>39,278</b>	<b>45,757</b>
Inventories		6,018	6,590
Accounts receivable		5,782	6,348
Other current receivables		2,026	2,263
Cash and cash equivalents	7	3,401	2,961
<b>Total current assets</b>		<b>17,227</b>	<b>18,162</b>
<b>TOTAL ASSETS</b>		<b>56,505</b>	<b>63,918</b>
<hr/>			
<b>Equity</b>		<b>29,494</b>	<b>33,210</b>
Provisions for pensions, interest-bearing	7	2,358	2,700
Lease liabilities, long-term	7	1,029	1,309
Interest-bearing liabilities, long-term	7	7,893	6,971
Deferred tax liabilities		1,754	2,172
Other provisions, long-term		485	615
Other non-interest-bearing liabilities, long-term		452	1,892
<b>Total long-term liabilities</b>		<b>13,970</b>	<b>15,660</b>
Lease liabilities, current	7	452	491
Interest-bearing liabilities, current	7	1,510	1,956
Other provisions, current		1,564	1,714
Accounts payable		2,118	2,398
Other non-interest-bearing liabilities, current		7,398	8,488
<b>Total current liabilities</b>		<b>13,042</b>	<b>15,047</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>56,505</b>	<b>63,918</b>

## Changes in equity for the Group

SEK M	Share capital	Other capital provided	Reserves <sup>1)</sup>	Retained earnings	Total	Non-controlling interests	Total equity
<b>Opening balance at January 1, 2024</b>	136	6,789	3,380	19,861	30,166	237	30,403
Total comprehensive income for the period	-	-	2,372	1,665	4,038	28	4,066
Dividend	-	-	-	-1,198	-1,198	-29	-1,228
Transactions with non-controlling interests	-	-	-	-	-	-31	-31
<b>Closing balance at December 31, 2024</b>	<b>136</b>	<b>6,789</b>	<b>5,752</b>	<b>20,328</b>	<b>33,005</b>	<b>205</b>	<b>33,210</b>
<b>Opening balance at January 1, 2025</b>	<b>136</b>	<b>6,789</b>	<b>5,752</b>	<b>20,328</b>	<b>33,005</b>	<b>205</b>	<b>33,210</b>
Total comprehensive income for the period	-	-	-4,752	2,378	-2,373	6	-2,367
Dividend	-	-	-	-1,253	-1,253	-14	-1,267
Transactions with non-controlling interests	-	-	-	50	50	-133	-83
<b>Closing balance at December 31, 2025</b>	<b>136</b>	<b>6,789</b>	<b>1,000</b>	<b>21,504</b>	<b>29,430</b>	<b>64</b>	<b>29,494</b>

1) Reserves pertain to cash flow hedges, hedges of net investments and translation differences.

## Condensed consolidated cash flow statement

SEK M	Note	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>Operating activities</b>					
Operating profit (EBIT)		1,371	1,084	3,789	2,854
Add-back of depreciation, amortization and write-downs	4	654	935	2,250	2,421
Other non-cash items <sup>1)</sup>		142	324	164	808
Add-back of restructuring costs <sup>2)</sup>		36	292	362	523
Paid restructuring costs		-151	-120	-338	-288
Financial items <sup>3)</sup> <sup>4)</sup>		-126	-142	-516	-542
Taxes paid		-116	-270	-574	-742
<b>Cash flow before changes in working capital</b>		<b>1,810</b>	<b>2,104</b>	<b>5,137</b>	<b>5,036</b>
<b>Changes in working capital</b>					
Inventories		418	815	-465	46
Operating receivables		-1,052	-1,561	-218	-712
Operating liabilities <sup>3)</sup>		378	680	-504	208
<b>Cash flow from operating activities</b>		<b>1,554</b>	<b>2,039</b>	<b>3,949</b>	<b>4,577</b>
<b>Investing activities</b>					
Acquisition of operations	9	-83	-169	-1,663	-3,256
Investments in intangible assets and tangible assets		-370	-353	-1,314	-1,309
Divestment of non-current assets		5	7	17	15
<b>Cash flow from investing activities</b>		<b>-447</b>	<b>-515</b>	<b>-2,960</b>	<b>-4,549</b>
<b>Financing activities</b>					
Change in interest-bearing liabilities		-495	-372	1,000	2,207
Depreciation of lease liabilities		-126	-137	-501	-506
Change in long-term receivables		0	2	3	31
Dividend paid		-4	-12	-1,267	-1,227
<b>Cash flow from financing activities</b>		<b>-625</b>	<b>-520</b>	<b>-765</b>	<b>504</b>
<b>Cash flow for the period</b>		<b>482</b>	<b>1,005</b>	<b>224</b>	<b>532</b>
Cash and cash equivalents at the beginning of the period		2,847	2,241	2,961	2,728
Translation differences		72	-284	216	-299
<b>Cash and cash equivalents at the end of the period</b>		<b>3,401</b>	<b>2,961</b>	<b>3,401</b>	<b>2,961</b>

1) The provision for field actions for Cardiosave had an impact of SEK 297 M and negotiations with CGU in Brazil had an impact of SEK 482 M in 2024.

2) Excluding write-downs on non-current assets

3) Non-cash financial items were reclassified to operating liabilities for the 2024 comparative figures.

4) Of which interest paid and received in the quarter amounted to SEK -119 M (-138) and other financial items to SEK -8 M (-4). Accumulated, interest paid and received amounted to SEK -490 M (-517) and other financial items to SEK -26 M (-25).

## Note 1 Accounting policies

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. For the Parent Company, the report has been prepared in accordance with the Swedish Annual Accounts Act and RFR 2. The accounting policies adopted are consistent with those applied for the 2024 Annual Report and should be read in conjunction with that Annual Report.

For practical reasons, the figures in this interim report have not been rounded off, which is why notes and tables may not total correct amounts. Unless otherwise specified, all figures pertain to SEK M and figures in parentheses pertain to the year-earlier period. The interim report provides alternative performance measures for monitoring the Group's operations.

## Note 2 Net sales

	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>Net sales, SEK M</b>				
Capital goods	4,184	4,688	11,968	12,421
<b>Recurring revenue</b>				
Product sales	4,170	4,467	16,185	15,588
Service assignments incl. spare parts	1,832	1,917	6,815	6,750
<b>Total recurring revenue</b>	<b>6,002</b>	<b>6,384</b>	<b>23,001</b>	<b>22,338</b>
<b>Total</b>	<b>10,186</b>	<b>11,071</b>	<b>34,969</b>	<b>34,759</b>
	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>Net sales, SEK M</b>				
<b>Revenue recognized at a point in time</b>				
Acute Care Therapies	4,747	5,179	17,499	16,808
Life Science	952	1,135	3,386	3,579
Surgical Workflows	3,161	3,497	9,626	10,403
<b>Total revenue recognized at a point in time</b>	<b>8,860</b>	<b>9,811</b>	<b>30,512</b>	<b>30,791</b>
<b>Revenue recognized over time</b>				
<b>Acute Care Therapies</b>				
Service	291	317	1,068	1,045
Profit from ongoing projects	-	0	-	0
Other revenue recognized over time	42	29	108	96
<b>Total Acute Care Therapies</b>	<b>333</b>	<b>347</b>	<b>1,176</b>	<b>1,140</b>
<b>Life Science</b>				
Service	62	92	260	356
Profit from ongoing projects	313	259	852	580
Other revenue recognized over time	-	6	0	38
<b>Total Life Science</b>	<b>375</b>	<b>358</b>	<b>1,112</b>	<b>973</b>
<b>Surgical Workflows</b>				
Service	514	465	1,870	1,625
Profit from ongoing projects	42	46	139	96
Other revenue recognized over time	61	45	160	134
<b>Total Surgical Workflows</b>	<b>617</b>	<b>556</b>	<b>2,170</b>	<b>1,855</b>
<b>Total revenue recognized over time</b>	<b>1,325</b>	<b>1,260</b>	<b>4,457</b>	<b>3,968</b>
<b>Total revenue recognized at a point in time and over time</b>	<b>10,186</b>	<b>11,071</b>	<b>34,969</b>	<b>34,759</b>

For further information about the distribution of sales for each business area, see pages 6-8.

## Note 3 Segment overview

	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>Net sales, SEK M</b>				
Acute Care Therapies	5,080	5,526	18,675	17,948
Life Science	1,328	1,492	4,498	4,552
Surgical Workflows	3,778	4,053	11,796	12,258
<b>Total</b>	<b>10,186</b>	<b>11,071</b>	<b>34,969</b>	<b>34,759</b>
<b>Gross profit, SEK M</b>				
Acute Care Therapies	2,834	2,790	10,420	9,615
Life Science	439	588	1,556	1,696
Surgical Workflows	1,531	1,676	4,679	4,842
<b>Total</b>	<b>4,803</b>	<b>5,053</b>	<b>16,654</b>	<b>16,153</b>
<b>Operating profit (EBIT), SEK M</b>				
Acute Care Therapies	864	347	3,021	2,065
Life Science	208	269	470	526
Surgical Workflows	436	600	773	703
Group functions and other (incl. eliminations) <sup>1)</sup>	-137	-132	-474	-440
<b>Operating profit (EBIT)</b>	<b>1,371</b>	<b>1,084</b>	<b>3,789</b>	<b>2,854</b>
Net financial items	-164	-173	-644	-571
<b>Profit after financial items</b>	<b>1,207</b>	<b>911</b>	<b>3,145</b>	<b>2,282</b>

1) Group functions and other refer mainly to central functions such as finance, communication, HR and other items, such as eliminations.

	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>Net sales, SEK M</b>				
EMEA	4,024	4,108	12,340	12,182
of which, Sweden	209	183	648	617
Americas	4,068	4,513	15,686	15,516
of which, USA	3,657	4,064	14,157	13,929
APAC	2,094	2,450	6,943	7,061
<b>Total</b>	<b>10,186</b>	<b>11,071</b>	<b>34,969</b>	<b>34,759</b>

## Note 4 Depreciation, amortization and write-downs

	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>SEK M</b>				
Acquired intangible assets	-140	-122	-434	-320
Intangible assets	-181	-468	-643	-928
Right-of-use assets	-131	-144	-523	-534
Tangible assets	-202	-202	-650	-639
<b>Total</b>	<b>-654</b>	<b>-935</b>	<b>-2,250</b>	<b>-2,421</b>
Write-downs included in total	-143	-357	-166	-357

	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>SEK M</b>				
Cost of goods sold	-234	-253	-953	-960
Selling expenses	-207	-204	-705	-625
Administrative expenses	-100	-104	-405	-414
Research and development costs	-120	-49	-175	-99
Restructuring costs	7	-325	-12	-325
<b>Total</b>	<b>-654</b>	<b>-935</b>	<b>-2,250</b>	<b>-2,421</b>
Write-downs included in total	-143	-357	-166	-357

## Note 5 Quarterly results

SEK M	Oct-Dec 2025	Jul-Sep 2025	Apr-Jun 2025	Jan-Mar 2025	Oct-Dec 2024	Jul-Sep 2024	Apr-Jun 2024	Jan-Mar 2024
Net sales	10,186	8,226	8,238	8,320	11,071	7,870	8,305	7,513
Cost of goods sold	-5,382	-4,411	-4,296	-4,225	-6,018	-4,315	-4,394	-3,880
<b>Gross profit</b>	<b>4,803</b>	<b>3,815</b>	<b>3,941</b>	<b>4,095</b>	<b>5,053</b>	<b>3,556</b>	<b>3,911</b>	<b>3,632</b>
Operating expenses	-3,432	-2,863	-3,074	-3,497	-3,969	-3,372	-3,081	-2,877
<b>Operating profit (EBIT)</b>	<b>1,371</b>	<b>952</b>	<b>867</b>	<b>598</b>	<b>1,084</b>	<b>184</b>	<b>830</b>	<b>755</b>
Net financial items	-164	-163	-147	-170	-173	-152	-130	-117
<b>Profit after financial items</b>	<b>1,207</b>	<b>789</b>	<b>721</b>	<b>428</b>	<b>911</b>	<b>32</b>	<b>700</b>	<b>638</b>
Taxes	-338	-214	-194	-124	-243	-24	-187	-174
<b>Net profit for the period</b>	<b>869</b>	<b>576</b>	<b>527</b>	<b>304</b>	<b>668</b>	<b>8</b>	<b>513</b>	<b>464</b>

## Note 6 Adjustment items

Adjusted EBITA, SEK M	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Acute Care Therapies	1,140	1,308	3,763	3,554
Life Science	172	293	490	608
Surgical Workflows	624	670	1,077	1,090
Group functions and other (incl. eliminations)	-127	-128	-450	-383
<b>Total</b>	<b>1,809</b>	<b>2,143</b>	<b>4,880</b>	<b>4,869</b>
Adjustments of EBITA, SEK M	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Specification of items affecting comparability that impact EBITA				
Restructuring costs, Acute Care Therapies	-11	-564	-293	-715
Restructuring costs, Life Science	-6	-9	-22	-35
Restructuring costs, Surgical Workflows	-12	-44	-59	-91
Write-down of R&D, Acute Care Therapies	-28	-	-28	-
Write-down of R&D, Surgical Workflows	-107	-	-107	-
Increased provision for contingent consideration, Acute Care Therapies <sup>1)</sup>	-179	-	-179	-
Dissolution of provisions for contingent consideration, Life Science <sup>1)</sup>	55	-	55	-
Provision for investigations with CGU in Brazil, Acute Care Therapies <sup>1)</sup>	-	-	-	-289
Provision for investigations with CGU in Brazil, Surgical Workflows <sup>1)</sup>	-	-	-	-193
Provision for field actions for Cardiosave, Acute Care Therapies <sup>2)</sup>	-	-297	-	-297
Other, Acute Care Therapies	-	-18	-	-18
Group functions and other (incl. eliminations)	-10	-5	-24	-57
<b>Total</b>	<b>-298</b>	<b>-937</b>	<b>-656</b>	<b>-1,695</b>
Items affecting comparability per segment				
Acute Care Therapies	-218	-879	-500	-1,319
Life Science	49	-9	33	-35
Surgical Workflows	-118	-44	-166	-284
Group functions and other (incl. eliminations)	-10	-5	-24	-57
<b>Total</b>	<b>-298</b>	<b>-937</b>	<b>-656</b>	<b>-1,695</b>

1) Reported in Other operating income and operating expenses  
2) Reported in Cost of goods sold

EBITA, SEK M	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Acute Care Therapies	921	429	3,264	2,235
Life Science	221	284	523	573
Surgical Workflows	506	626	911	806
Group functions and other (incl. eliminations)	-137	-132	-474	-440
<b>Total</b>	<b>1,511</b>	<b>1,206</b>	<b>4,223</b>	<b>3,174</b>

Adjustments of EBIT, SEK M	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Items affecting comparability that impact EBITA (according to above)	-298	-937	-656	-1,695
Items affecting comparability that impact EBIT but not EBITA <sup>1)</sup>	-48	-	-48	-
<b>Total</b>	<b>-346</b>	<b>-937</b>	<b>-704</b>	<b>-1,695</b>

1) Write-down of acquired intangible assets, Surgical Workflows. Reported in Operating expenses

	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>Effect of adjustment of tax, SEK M</b>				
Amortization and write-down of acquired intangible assets <sup>1)</sup>	92	122	386	320
Items affecting comparability	346	937	704	1,695
<b>Adjustment items, total</b>	<b>438</b>	<b>1,059</b>	<b>1091</b>	<b>2,016</b>
Tax on adjustment items <sup>2)</sup>	-94	-284	-273	-459
Adjustment for tax items affecting comparability	-	-	-	-
<b>Total</b>	<b>-94</b>	<b>-284</b>	<b>-273</b>	<b>-459</b>

1) Excluding write-downs classified as items affecting comparability

2) Tax effect on tax deductible adjustment items

## Note 7 Consolidated net interest-bearing debt

SEK M	December 31	
	2025	2024
Interest-bearing liabilities, current	1,510	1,956
Interest-bearing liabilities, long-term	7,893	6,971
Provisions for pensions, interest-bearing	2,358	2,700
Lease liabilities, current	452	491
Lease liabilities, long-term	1,029	1,309
<b>Interest-bearing liabilities</b>	<b>13,241</b>	<b>13,428</b>
Less cash and cash equivalents	-3,401	-2,961
<b>Net interest-bearing cash/debt</b>	<b>9,840</b>	<b>10,467</b>

## Note 8 Key figures for the Group

	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>Financial and operative key figures</b>				
<b>Key figures based on Getinge's financial targets</b>				
Adjusted earnings per share <sup>1)</sup> , SEK	4.45	5.28	11.29	11.73
Growth in adjusted earnings per share <sup>1)</sup> , %	-15.7	69.8	-3.7	27.6
<b>Other operative and financial key figures</b>				
Organic growth in order intake, %	2.3	7.4	3.5	6.3
Organic growth in net sales, %	1.2	9.2	4.9	4.9
Gross margin, %	47.2	45.6	47.6	46.5
Selling expenses, % of net sales	15.4	14.6	17.3	17.2
Administrative expenses, % of net sales	11.6	12.1	13.1	13.4
Research and development costs, gross as a % of net sales	6.2	5.5	6.0	6.0
Operating margin, %	13.5	9.8	10.8	8.2
EBITDA, SEK M	2,025	2,020	6,039	5,275
Average number of shares, thousands	272,370	272,370	272,370	272,370
Number of shares at the end of the period, thousands	272,370	272,370	272,370	272,370
Interest-coverage ratio, multiple			11.2	12.3
Net debt/equity ratio, multiple			0.33	0.32
Net debt/Rolling 12m adjusted EBITDA, multiple			1.5	1.6
Capital employed, SEK M			40,934	40,952
Return on capital employed, %			11.0	11.1
Return on equity, %			7.5	5.2
Equity/assets ratio, %			52.2	52.0
Equity per share, SEK			108.28	121.93
Number of employees			11,670	11,791

1) Before and after dilution

## Alternative performance measures

Alternative performance measures refer to financial measures used by the company's management and investors to evaluate the Group's earnings and financial position and that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the Group's performance. Accordingly, the alternative performance measures should be considered a supplement to the financial statements prepared in accordance with IFRS. The financial measures recognized in this report may differ from similar measures used by other companies.

	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
<b>Calculation of organic net sales</b>				
<b>Net sales</b>	<b>10,186</b>	<b>11,071</b>	<b>34,969</b>	<b>34,759</b>
<i>Add-back of:</i>				
Currency translation	1,023	36	2,216	423
Acquired operations	-	-294	-735	-1,794
<b>Net sales, organic</b>	<b>11,209</b>	<b>10,813</b>	<b>36,451</b>	<b>33,387</b>
<b>Adjusted gross profit, SEK M</b>	<b>Oct-Dec 2025</b>	<b>Oct-Dec 2024</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
<b>Gross profit</b>	<b>4,803</b>	<b>5,053</b>	<b>16,654</b>	<b>16,153</b>
<i>Add-back of:</i>				
Depreciation, amortization and write-downs of intangible assets and tangible assets	234	253	953	960
Other items affecting comparability	-	297	-	297
Adjustment for write-downs included in other items affecting comparability	-	-	-	-
<b>Adjusted gross profit</b>	<b>5,037</b>	<b>5,604</b>	<b>17,607</b>	<b>17,409</b>
<b>Adjusted EBITDA, SEK M</b>	<b>Oct-Dec 2025</b>	<b>Oct-Dec 2024</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
<b>Operating profit (EBIT)</b>	<b>1,371</b>	<b>1,084</b>	<b>3,789</b>	<b>2,854</b>
<i>Add-back of:</i>				
Depreciation, amortization and write-downs of intangible assets and tangible assets	562	535	1,864	1,823
Amortization and write-down of acquired intangible assets	92	122	386	320
Other items affecting comparability	307	315	307	797
Acquisition and restructuring costs	39	622	397	898
Adjustment for write-downs included in other items affecting comparability and restructuring costs	-143	-46	-162	-46
<b>Adjusted EBITDA</b>	<b>2,228</b>	<b>2,632</b>	<b>6,581</b>	<b>6,646</b>
<b>Adjusted EBITA, SEK M</b>	<b>Oct-Dec 2025</b>	<b>Oct-Dec 2024</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
<b>Operating profit (EBIT)</b>	<b>1,371</b>	<b>1,084</b>	<b>3,789</b>	<b>2,854</b>
<i>Add-back of:</i>				
Amortization and write-down of acquired intangible assets	92	122	386	320
Other items affecting comparability	307	315	307	797
Acquisition and restructuring costs	39	622	397	898
<b>Adjusted EBITA</b>	<b>1,809</b>	<b>2,143</b>	<b>4,880</b>	<b>4,869</b>
<b>Adjusted EBIT, SEK M</b>	<b>Oct-Dec 2025</b>	<b>Oct-Dec 2024</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
<b>Operating profit (EBIT)</b>	<b>1,371</b>	<b>1,084</b>	<b>3,789</b>	<b>2,854</b>
<i>Add-back of:</i>				
Other items affecting comparability	307	315	307	797
Acquisition and restructuring costs	39	622	397	898
<b>Adjusted EBIT</b>	<b>1,717</b>	<b>2,021</b>	<b>4,494</b>	<b>4,549</b>
<b>Adjusted net profit for the period, SEK M</b>	<b>Oct-Dec 2025</b>	<b>Oct-Dec 2024</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
<b>Net profit for the period</b>	<b>869</b>	<b>668</b>	<b>2,276</b>	<b>1,654</b>
<i>Add-back of:</i>				
Amortization and write-down of acquired intangible assets	92	122	386	320
Other items affecting comparability	307	315	307	797
Acquisition and restructuring costs	39	622	397	898
Tax items affecting comparability	-	-	-	-
Tax on add-back items	-94	-284	-273	-459
<b>Adjusted net profit for the period</b>	<b>1,213</b>	<b>1,443</b>	<b>3,093</b>	<b>3,211</b>

The calculation of adjusted earnings per share, before and after dilution, attributable to Parent Company shareholders, is based on the following information:

**Earnings (numerator), SEK M**

	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Adjusted net profit for the period	1,213	1,443	3,093	3,211
Adjusted net profit for the period attributable to non-controlling interest	-1	-5	-17	-16
<b>Adjusted net profit for the period attributable to the Parent Company shareholders, which form the basis for calculation of adjusted earnings per share</b>	<b>1,212</b>	<b>1,438</b>	<b>3,076</b>	<b>3,195</b>
<b>Number of shares (denominator)</b>	<b>Oct-Dec 2025</b>	<b>Oct-Dec 2024</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
Weighted average number of ordinary shares for calculation of adjusted earnings per share (thousands)	272,370	272,370	272,370	272,370
<b>Adjusted earnings per share, SEK</b>	<b>4.45</b>	<b>5.28</b>	<b>11.29</b>	<b>11.73</b>

The calculation of adjusted EBITA margin, adjusted for currency impact and tariff cost, is based on the following information:

**Adjusted EBITA (numerator), SEK M**

	Oct-Dec 2025	Jan-Dec 2025
Adjusted EBITA	1,809	4,880
<i>Add-back of:</i>		
Currency impact	316	686
Tariff cost	148	367
<b>Adjusted EBITA, adjusted for currency impact and tariff cost</b>	<b>2,273</b>	<b>5,932</b>
<b>Net Sales (denominator)</b>	<b>Okt-Dec 2025</b>	<b>Jan-Dec 2025</b>
Net Sales	10,186	34,759
<i>Add-back of:</i>		
Currency impact	1,023	2,216
<b>Net sales, adjusted for currency impact</b>	<b>11,209</b>	<b>37,185</b>
<b>Adjusted EBITA-margin, adjusted for currency impact and tariff cost, %</b>	<b>20.3</b>	<b>16.0</b>

## Note 9 Acquisitions

### Acquisitions in 2025

	2025	2024
<b>Net assets acquired, SEK M</b>		
Intangible assets	-	3,241
Tangible assets	-	23
Deferred tax assets	-	25
Inventories	-	93
Accounts receivable	-	142
Other current receivables	-	8
Cash and cash equivalents	-	115
Deferred tax liabilities	-	-755
Accounts payable	-	-32
Other non-interest-bearing liabilities	-	-57
<b>Identifiable net assets</b>	<b>-</b>	<b>2,802</b>
Goodwill	-	3,103
<b>Total purchase prices</b>	<b>-</b>	<b>5,905</b>
<i>Deductible and additional items</i>		
Additional purchase prices and other adjustments	1,580	290
Acquisition of shares from non-controlling interests	83	31
Unpaid purchase prices	-	-2,855
Cash and cash equivalents in acquired businesses	-	-115
<b>Impact on the Group's cash and cash equivalents</b>	<b>1,663</b>	<b>3,256</b>

In September 2024, 100% of the shares in Paragonix Technologies, Inc. were acquired. Additional purchase prices of SEK 1,555 M were paid in 2025 for the achievement of performance-related and regulatory milestones. In addition, the acquisition balance sheet was adjusted, which resulted in a reduced purchase price of SEK 19 M. Additional purchase prices of SEK 44 M were paid for Irasun GmbH in 2025. Shares were also acquired from non-controlling interests in the subsidiary Pulsion Medical Systems SE, after which the Getinge Group owns all of the shares in the company. The acquisition price amounted to SEK 83 M and the transaction was recognized in equity.

#### Contingent considerations

Getinge signed agreements on contingent considerations in connection with acquisitions of assets and subsidiaries. Liabilities for these additional purchase prices are measured at fair value through profit or loss at Level 3 of the fair value hierarchy. The additional purchase prices are contingent on securing government approval for the acquired product development projects and contingent on the earnings performance of the acquired businesses. Future cash flows are discounted if the planned payment date exceeds 12 months. Assessments of future cash flows related to the contingent consideration are regularly reviewed by company management and recognized at fair value. The discount effect is recognized in profit or loss under financial items on an ongoing basis.

In 2025, Paragonix Technologies, Inc. exceeded the performance-related milestones recognized in connection with the acquisition and an additional non-interest-bearing liability of SEK 179 M related to contingent consideration was recognized in the fourth quarter of 2025. Getinge Aseptic Solutions was also acquired in 2024, and updated assessments have resulted in the dissolution in the fourth quarter of SEK 55 M of the contingent consideration that was recognized in connection with the acquisition.

Contingent considerations	December 31	December 31
	2025	2024
<b>Opening balance</b>	<b>3,280</b>	<b>498</b>
Business combinations	-	3,112
Dissolution of provision	-55	-13
Fair value adjustments recognized in profit or loss	184	11
Payments	-1,599	-512
Discount effect	77	32
Translation differences	-443	152
<b>Closing balance</b>	<b>1,444</b>	<b>3,280</b>

## Parent Company financial statements

### Condensed Parent Company's income statement

SEK M	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Net sales	91	69	348	293
Administrative expenses	-115	-85	-397	-328
<b>Operating loss</b>	<b>-24</b>	<b>-16</b>	<b>-49</b>	<b>-35</b>
Result from participations in Group companies <sup>1)</sup>	-	12	2,134	1,743
Interest income and other similar income <sup>2)</sup>	10	12	55	37
Interest expenses and other similar expenses <sup>2)</sup>	-53	-55	-220	-218
<b>Profit/loss after financial items</b>	<b>-67</b>	<b>-47</b>	<b>1,920</b>	<b>1,527</b>
Appropriations	60	139	60	139
Taxes	-18	-34	-24	-39
<b>Net profit for the period<sup>3)</sup></b>	<b>-25</b>	<b>58</b>	<b>1,956</b>	<b>1,627</b>

1) Primarily refers to dividends from Group companies that take place on an ongoing basis throughout the year.

2) Interest income and other similar income and interest expenses and other similar expenses include exchange-rate gains and losses attributable to the translation of financial receivables and liabilities measured in foreign currencies

3) Comprehensive income for the period corresponds to net profit for the period

## Condensed Parent Company's balance sheet

SEK M	December 31 2025	December 31 2024
<b>Assets</b>		
Tangible assets	1	2
Participations in Group companies	31,572	29,582
Deferred tax assets	97	99
Current receivables from Group companies	974	1,244
Current receivables	40	18
Cash and bank balances	2	0
<b>Total assets</b>	<b>32,687</b>	<b>30,946</b>
<b>Equity and liabilities</b>		
Equity	26,372	25,669
Long-term liabilities	5,394	3,595
Other provisions	18	16
Current liabilities to Group companies	7	7
Current liabilities	896	1,660
<b>Total equity and liabilities</b>	<b>32,687</b>	<b>30,946</b>

# Definitions

## Financial terms

**Adjusted earnings per share:** Adjusted net profit for the period attributable to Parent Company shareholders in relation to average number of shares.

**Adjusted EBIT:** Operating profit (EBIT) with add-back of acquisition and restructuring costs and other items affecting comparability.

**Adjusted EBITA:** EBITA with add-back of acquisition and restructuring costs and other items affecting comparability.

**Adjusted EBITDA:** EBITDA with add-back of acquisition and restructuring costs and other items affecting comparability.

**Adjusted gross profit:** Gross profit with add-back of depreciation, amortization and write-downs and other items affecting comparability.

**Adjusted net profit for the period:** Net profit for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs, other items affecting comparability and tax effect of add-back of income-statement items.

**Adjusted profit before tax:** Profit before tax for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs and other items affecting comparability.

**Capital employed:** Average total assets with add-back of cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.

**Capital goods:** Durable products that are not consumed when used.

**Currency transaction effect:** Exchange of current year's volumes of foreign currency at this year's exchange rates, compared with the exchange rates in the preceding year.

**Earnings per share:** Net profit attributable to Parent Company shareholders in relation to average number of shares.

**EBIT:** Operating profit.

**EBITA margin:** EBITA in relation to net sales.

**EBITA:** Operating profit (EBIT) before add-back of amortization and write-down of acquired intangible assets.

**EBITDA margin:** EBITDA in relation to net sales.

**EBITDA:** Operating profit (EBIT) with add-back of amortization, depreciation and write-downs.

**Equity per share:** Equity in relation to the number of shares at the end of the period.

**Equity/assets ratio:** Equity in relation to total assets.

**Free cash flow:** Cash flow from operating activities and investing activities, excluding acquisitions and divestment of operations.

**Gross margin:** Gross profit in relation to net sales.

**Interest-coverage ratio:** Rolling 12 months' adjusted EBITDA in relation to rolling 12 months' net interest.

**Items affecting comparability:** Acquisition and restructuring costs and other items affecting comparability. Other items affecting comparability are significant revenue/expenses that impact comparability between accounting periods. These items include, but are not limited to, write-downs, disputes and major gains and losses attributable to divestments of assets or businesses.

**Net debt/equity ratio:** Net interest-bearing debt in relation to equity.

**Operating liabilities:** Accounts payable, other provisions and other non-interest-bearing liabilities (contract liabilities, non-interest-bearing provisions for pensions and similar obligations, accrued expenses and deferred income as well as other liabilities).

**Operating margin:** Operating profit (EBIT) in relation to net sales.

**Operating receivables:** Accounts receivable and other current receivables (contract assets, prepaid expenses and accrued income, and other receivables).

**Organic change:** A financial change adjusted for currency, acquisitions and divestments of operations.

**Adjusted to the following from first quarter of 2026:**

A financial change adjusted for currency, acquisitions and divestments of operations and phase-out of product categories.

**Recurring revenue:** Revenue from sales of products that are continuously consumed as well as service, spare parts and similar items.

**Return on capital employed:** Rolling 12 months' adjusted EBIT in relation to capital employed.

**Return on equity:** Rolling 12 months' profit after tax in relation to average equity.

and opportunities for the organization. The results are also used to determine whether a sustainability topic is to be included in the company's sustainability report.

**Employee engagement:** The engagement score in Getinge's employee survey.

**ESRS:** European Sustainability Reporting Standards.

**Online customer training:** The number of training courses held for customers. The total number of times a customer has completed an e-learning course or participated in a training webinar.

**REC (Renewable Energy Certificates):** Used to certify that electricity was generated from renewable sources.

**Scope 1 & 2:** Carbon emissions from production (in ton CO<sub>2</sub> equivalents). Scope 1 includes emissions from oil and gas consumption. Emissions from Getinge's vehicle fleet are excluded in the interim report but the amounts for the full-year are presented in the Sustainability Report. Scope 2 includes emissions from electricity, heating and cooling. Emissions from leased premises are excluded in the interim report but the amounts for the full-year are presented in the Sustainability Report.

**Scope 3:** Includes other indirect emissions, both upstream and downstream in the value chain, arising from activities such as freight transport, purchased goods and services, as well as emissions from the use of products sold.

**WRAR (Work Related Accident Rate):** The number of work related accidents divided by the number of hours worked, normalized by multiplying by 200,000 hours.

## Medical terms

**Cardiopulmonary:** Pertaining or belonging to both heart and lung.

**Cardiovascular:** Pertaining or belonging to both heart and blood vessels.

**DPTE®-BetaBags:** Bag that ensures contamination-free transfer of components.

**ECMO:** Extracorporeal membrane oxygenation, meaning oxygenation outside the body through a membrane. Put simply, a modified cardiac and respiratory machine that exchanges oxygen and carbon dioxide, like an artificial lung.

**Endoscope:** Equipment for visual examination of the body's cavities, such as the stomach.

**Endovascular:** Vascular treatment using catheter technologies.

## Sustainability terms

**Double materiality assessment:** The process of identifying an organization's impacts on people and the environment and the sustainability-related financial risks

**EVH** Endoscopic Vessel Harvesting is a minimally invasive technique for removing blood vessels, for example during coronary artery bypass surgery.

**Extracorporeal life support (ECLS):** Oxygenation of the patient's blood outside the body (extracorporeal) using advanced medical technology.

**Grafts:** Artificial vascular implants.

**Hemodynamic monitoring:** Monitoring the balance between blood pressure and blood flow.

**Low temperature sterilization:** A device used to sterilize surgical instruments which cannot be sterilized with high temperature steam. It is mainly used for instruments

used in the minimal invasive and robotic surgery.

**NAVA:** Neurally Adjusted Ventilatory Assist (NAVA) identifies the electric activity that activates the diaphragm and using these signals adapts the ventilation to the patient's respiratory rhythm.

**Perfusionist:** A healthcare professional who operates the heart-lung machine during surgery.

**Stent:** A tube for endovascular widening of blood vessels.

**Sterilizer:** A device to eliminate microorganisms on surgical instruments, usually by high temperature with steam.

**Vascular intervention:** A medical procedure conducted through vascular puncturing instead of using an open surgery method.

**Ventilator:** Medical device to help patients breath.

**Vessel harvesting:** The name of the process for removing blood vessels from the body.

**WIS:** The product category of washers, isolators and sterilizers.

### Geographic areas

**Americas:** North, South and Central America.

**APAC:** Asia and Pacific (excluding Middle East).

**EMEA:** Europe, Middle East and Africa.

## Teleconference

A teleconference with President & CEO Mattias Perjos and CFO Agneta Palmér will be held on January 27, 2026 at 10:00–11:00 a.m. CET.

Fund managers, analysts and the media are invited to the teleconference.

Register via <https://getinge.events.inderes.com/q4-report-2025> to participate in the teleconference. After registering, you will receive a telephone number and a conference ID to log in to the teleconference. You can ask questions verbally at the teleconference.

A presentation will be held during the telephone conference. To access the presentation, click on <https://events.inderes.com/getinge/q4-report-2025/dial-in>. A recording will be available <https://events.inderes.com/getinge/q4-report-2025/dial-in> for three years.

## Financial information

Updated information on, for example, the Getinge share and corporate governance is available on Getinge's website [www.getinge.com](http://www.getinge.com). The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at [www.getinge.com](http://www.getinge.com). The preliminary dates for financial communication are provided below:

March 26, 2026	Annual Report 2025
April 21, 2026	Q1 Report 2026
April 21, 2026	Annual General Meeting
July 17, 2026	Q2 Report 2026
October 20, 2026	Q3 Report 2026
January 26, 2027	Q4 and Year-end report 2026

## Contact

David Kördel, Head of Investor Relations  
+46 (0)10 335 0077  
[david.kordel@getinge.com](mailto:david.kordel@getinge.com)

This information is such that Getinge AB (publ) is obligated to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on January 27, 2026 at 8:00 a.m. CET.

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs about 12,000 people worldwide and the products are sold in more than 135 countries.

Getinge has been listed on Nasdaq OMX Stockholm, Nordic Large Cap since 1993.